DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rpl5sc/pharmapoint) has announced the addition of the "Systemic Lupus Erythematosus and Lupus Nephritis - France Drug Forecast and Market Analysis to 2022" report to their offering.
Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.
- Overview of SLE-LN including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in France from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting France SLE-LN market.
Key Topics Covered:
1 Table of Contents
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.3 Quality of Life
4 Disease Management
4.1 Diagnosis Overview
4.2 Treatment Overview
5 Competitive Assessment
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
6 Opportunity and Unmet Need
6.2 Unmet Needs
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/rpl5sc/pharmapoint